Dr. Strati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 507-284-2511
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2014 - 2016
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2014
- Universita San RaffaeleClass of 2008
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2018 - 2027
- AZ State Medical License 2022 - 2026
- GA State Medical License 2022 - 2026
- LA State Medical License 2022 - 2026
- TN State Medical License 2022 - 2026
- WA State Medical License 2022 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma Start of enrollment: 2020 Jul 16
- Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Start of enrollment: 2020 Jul 27
- A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Start of enrollment: 2022 Sep 23
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani
Blood. 2025-02-12 - Phase II trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.Dai Chihara, Raphael E Steiner, Ranjit Nair, Lei Feng, Sairah Ahmed
Blood Advances. 2025-02-05 - Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Confere...Alexey V Danilov, Craig Sauter, Tycel Phillips, Catherine C Coombs, Andrew Ip
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-13
Abstracts/Posters
- A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent LymphomaPaolo Strati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...Paolo Strati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Prognostic value of baseline SUV in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- MD Anderson Research Highlights for January 22, 2025January 22nd, 2025
- MD Anderson Unveils January 2025 Research Breakthroughs in Cancer ScienceJanuary 22nd, 2025
- Crystal Ball Cloudy for PI3K Inhibitors' Future in HematologyJanuary 2nd, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: